Abk Biomedical Inc
Halifax, CA · Nova Scotia, Canada corporation · 3 known investors
ABK Biomedical is a clinical-stage medical device company developing imageable microsphere products for treating cancer, including Eye90 microspheres for Y90 radioembolization in liver cancer and Easi-Vue embolic microspheres for embolization of arteriovenous malformations and hypervascular tumors. Its products are aimed at interventional oncology and radioembolization procedures.
BiotechHealthtechMedical Devices
Founders & leadership
BA
Bob AbrahamFounder
AH
Anthony HeadleyExecutive
GD
Gary DonofrioExecutive
MM
Michael ManganoExecutive
DD
David DobrowskyExecutive
LB
Lucy BataneantExecutive
MG
Marc GregoireExecutive
MT
Mike TysonExecutive
DD
David DobrowskiExecutive
JM
James McLarenNamed on SEC filing
RO
Robert OrrNamed on SEC filing
Board
KP
Keten PatelBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$80.7M disclosed across 4 rounds · 2019–2025
▶$2.6MraisedNov 2025 · 6 investors · OtherRule 506(b)
▶$2.6MraisedNov 2025 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Lucy BataneantExecutive Officer
- Aravind ArepallyExecutive Officer
- David DobrowskyExecutive Officer
- Joseph SilettoDirector
- James McLarenDirector
- Marc GregoireExecutive Officer
- Aaron BerezDirector
- Keten PatelDirector
- Anthony HeadleyExecutive Officer
- Carissa Bellardine BlackDirector
- Mike TysonExecutive Officer
- James EadieDirector
- Gary DonofrioExecutive Officer
- Michael ManganoExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Oct 2025
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$26.1MraisedMay 2025 · 24 investors · OtherRule 506(b)
▶$26.1MraisedMay 2025 · 24 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony HeadleyExecutive Officer
- Gary DonofrioExecutive Officer
- Michael ManganoExecutive Officer, Director
- David DobrowskyExecutive Officer
- Keten PatelDirector
- Lucy BataneantExecutive Officer
- Joseph SilettoDirector
- Marc GregoireExecutive Officer
- Carissa Bellardine BlackDirector
- Aaron BerezDirector
- James EadieDirector
- Mike TysonExecutive Officer
- James McLarenDirector
- Aravind ArepallyExecutive Officer
- Offering amount
- $26.1M
- Amount sold
- $26.1M
- First sale
- Apr 2025
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$28.5MraisedDec 2022 · 23 investors · OtherRule 506(b)
▶$28.5MraisedDec 2022 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony HeadleyExecutive Officer
- Ketan PatelDirector
- Marc GregoireExecutive Officer
- Aravind ArepallyExecutive Officer
- Michael ManganoExecutive Officer, Director
- David DobrowskiExecutive Officer
- Aaron BerezDirector
- James McLarenDirector
- Mike TysonExecutive Officer
- Gary DonofrioExecutive Officer
- Carissa BlackDirector
- Offering amount
- $28.5M
- Amount sold
- $28.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$23.5MraisedApr 2019 · 10 investors · BiotechnologyRule 506(b)
▶$23.5MraisedApr 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James McLarenDirector
- Michael TysonExecutive Officer
- David DobrowskiExecutive Officer
- Robert OrrDirector
- Aaron BerezDirector
- Bob AbrahamExecutive Officer, Director
- Marc GregoireExecutive Officer
- Michael ManganoExecutive Officer, Director
- Gary DonofrioExecutive Officer
- Offering amount
- $23.5M
- Amount sold
- $23.5M
- First sale
- Apr 2019
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapIQVIA8 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Abbott7 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Companies competing with Abk Biomedical Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Abk Biomedical Inc do?
- ABK Biomedical is a clinical-stage medical device company developing imageable microsphere products for treating cancer, including Eye90 microspheres for Y90 radioembolization in liver cancer and Easi-Vue embolic microspheres for embolization of arteriovenous malformations and hypervascular tumors. Its products are aimed at interventional oncology and radioembolization procedures.
- Who founded Abk Biomedical Inc?
- Abk Biomedical Inc was founded by Bob Abraham.
- Who are Abk Biomedical Inc's investors?
- Abk Biomedical Inc's investors include Eight Roads Ventures, F-Prime Capital Partners, Vivo Capital.
- How much funding has Abk Biomedical Inc raised?
- Abk Biomedical Inc has disclosed $80.7M raised across 4 rounds.
- Where is Abk Biomedical Inc headquartered?
- Abk Biomedical Inc is headquartered in Halifax, CA.